Skip to main content
Clinical Trials/NCT05224986
NCT05224986
Recruiting
Not Applicable

Lifestyle Patterns and Glycemic Control

Columbia University1 site in 1 country34 target enrollmentStarted: January 19, 2022Last updated:
ConditionsPre-diabetes
InterventionsFixed Schedule

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
34
Locations
1
Primary Endpoint
Adipose Tissue Measurement - Subcutaneous

Overview

Brief Summary

The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes.

The investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.

Detailed Description

Variability in lifestyle behaviors has been associated with adverse health, specifically poor glucose control. The project proposes to test whether reducing this variability improves glycemia in patients with pre-diabetes. If successful, this simple positive lifestyle message to keep stable behaviors has the potential to improve the health of millions of adults worldwide.

This project will enroll participants with pre-diabetes who have erratic lifestyle behaviors and randomize them to either maintain their usual habits (control group) or stabilize their behaviors (stability group). Both groups will be followed for 12 weeks. Before the start of the 12-week period, all participants will track their sleep for 2 weeks and will wear a glucose monitor to measure their glucose levels. At the start and end of the 12-week period, they will come to the research lab to undergo a glucose tolerance test. This test will measure how their body reacts to a glucose load. They will also undergo magnetic resonance imaging and spectroscopy scanning. This scan will provide information on body composition and liver fat content.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Single (Outcomes Assessor)

Masking Description

Participants will not be blinded to the intervention or purpose of the study but will be told that rest-activity patterns will be examined in the context of well-being and that we will test the influence of these lifestyle patterns on glucose control and body composition. Although the investigators and research assistant directly involved in the conduct of the study cannot be blinded to participant assignment to the intervention or control group, the technicians involved in sample processing and the biostatistician (Dr. Cheng) will be blinded to this information to reduce the risk of bias.

Eligibility Criteria

Ages
25 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.9%)
  • 25 years or older
  • BMI between 25-39.9 kg/m2
  • Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)
  • Variable bedtime, SD≥45 minutes.

Exclusion Criteria

  • Chronic Kidney Disease (GFR\<60)
  • Uncontrolled hypertension (≥160/100 mmHg)
  • Obstructive Sleep Apnea
  • Psychiatric or neurological disorder
  • Prevalent cardiovascular disease
  • Dyslipidemia (triglycerides≥200 mg/dL)
  • Medications that affect insulin sensitivity, glucose concentrations, and body weight
  • Non-day or rotating shift workers
  • Travel across time zones
  • Active participation in weight loss program or within past 3 months

Arms & Interventions

Variable Schedule

No Intervention

Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks.

Fixed Schedule

Experimental

Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks.

Intervention: Fixed Schedule (Behavioral)

Outcomes

Primary Outcomes

Adipose Tissue Measurement - Subcutaneous

Time Frame: 12 weeks

Measurement of subcutaneous adiposity using MRI.

Adipose Tissue Measurement - Total

Time Frame: 12 weeks

Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue.

Adipose Tissue Measurement - Visceral

Time Frame: 12 weeks

Measurement of visceral adiposity using MRI.

Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose

Time Frame: 12 weeks

Testing glucose variability. The primary outcome variables are mean amplitude of glucose excursion and standard deviation of average glucose.

Glucose Area Under Curve

Time Frame: 12 weeks

Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test.

Secondary Outcomes

  • Liver Fat Content(12 weeks)
  • Endothelial cell inflammation (sub-set, n≤10)(Baseline, 12 weeks)
  • Endothelial cell oxidative stress (sub-set, n≤10)(Baseline, 12 weeks)
  • White blood cells(Baseline, 12 weeks)
  • Disposition Index(12 weeks)
  • Short-term Change in Glycemia(Baseline, up to 12 weeks)
  • Long-term Change in Glycemia(Baseline, 12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Marie-Pierre St-Onge

Associate Professor of Nutritional Medicine

Columbia University

Study Sites (1)

Loading locations...

Similar Trials